139 related articles for article (PubMed ID: 11898261)
21. [New insights into the combinability of Eloxation (oxaliplatin): present and future prospects].
Longo F
Tumori; 2003; 89(1):A1-2. PubMed ID: 12729376
[No Abstract] [Full Text] [Related]
22. A historical perspective on oxaliplatin: rethinking the role of platinum compounds and learning from near misses.
Cvitkovic E
Semin Oncol; 1998 Apr; 25(2 Suppl 5):1-3. PubMed ID: 9609102
[No Abstract] [Full Text] [Related]
23. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
24. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Grivicich I; Mans DR; Peters GJ; Schwartsmann G
Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
[TBL] [Abstract][Full Text] [Related]
25. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
[TBL] [Abstract][Full Text] [Related]
26. In vitro schedule-dependent interaction between melphalan and oxaliplatin in human colorectal cancer cell lines.
van Iersel LB; Koudijs TM; Hoekman EJ; Janssen-van Rhijn CM; Vahrmeijer AL; Nortier JW; van de Velde CJ; Gelderblom H; Kuppen PJ
J Surg Res; 2011 May; 167(2):273-8. PubMed ID: 20036390
[TBL] [Abstract][Full Text] [Related]
27. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea.
Takemoto H; Nishimura J; Komori T; Kim HM; Ota H; Suzuki R; Ikenaga M; Ikeda M; Yamamoto H; Satoh T; Hata T; Takemasa I; Mizushima T; Doki Y; Mori M;
Int J Clin Oncol; 2017 Feb; 22(1):88-95. PubMed ID: 27465476
[TBL] [Abstract][Full Text] [Related]
28. [Promising effects of pregabalin in the treatment of oxaliplatin-induced sensory neuropathy in patients with colorectal carcinoma].
Nagahara H; Noda E; Maeda K; Inoue T; Hirakawa T; Hasegawa T; Shibutani M; Hirakawa K
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1181-3. PubMed ID: 24047775
[TBL] [Abstract][Full Text] [Related]
29. Integrative Medicine for Relief of Nausea and Vomiting in the Treatment of Colorectal Cancer Using Oxaliplatin-Based Chemotherapy: A Systematic Review and Meta-Analysis.
Chen MH; May BH; Zhou IW; Zhang AL; Xue CC
Phytother Res; 2016 May; 30(5):741-53. PubMed ID: 26912094
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
Shahriari-Ahmadi A; Fahimi A; Payandeh M; Sadeghi M
Asian Pac J Cancer Prev; 2015; 16(17):7603-6. PubMed ID: 26625769
[TBL] [Abstract][Full Text] [Related]
32. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life.
Stefansson M; Nygren P
Acta Oncol; 2016; 55(9-10):1227-1235. PubMed ID: 27550718
[TBL] [Abstract][Full Text] [Related]
33. Oxaliplatin in colorectal cancer: an overview.
Armand JP; Boige V; Raymond E; Fizazi K; Faivre S; Ducreux M
Semin Oncol; 2000 Oct; 27(5 Suppl 10):96-104. PubMed ID: 11049040
[No Abstract] [Full Text] [Related]
34. [January 2004: a month of success with oxaliplatin and hope for patients with colorectal cancer].
Tumori; 2004; 90(1):suppl 28-30. PubMed ID: 15143997
[No Abstract] [Full Text] [Related]
35. Oxaliplatin (L-OHP): a new reality in colorectal cancer.
Bleiberg H
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):1-3. PubMed ID: 9647611
[TBL] [Abstract][Full Text] [Related]
36. Xaliproden lessens oxaliplatin-mediated neuropathy.
Susman E
Lancet Oncol; 2006 Apr; 7(4):288. PubMed ID: 16598880
[No Abstract] [Full Text] [Related]
37. Oxaliplatin: third-generation platinum analog.
Wilkes G
Clin J Oncol Nurs; 2003; 7(3):353-6. PubMed ID: 12793347
[No Abstract] [Full Text] [Related]
38. [Phase II clinical trial of oxaliplatin alone for refractory advanced colorectal cancer].
Xu RH; Guan ZZ; Feng FY; He XH; Liu SJ; Di LJ; Li SF; Li LQ
Ai Zheng; 2003 Aug; 22(8):874-6. PubMed ID: 12917039
[TBL] [Abstract][Full Text] [Related]
39. [ASCO 2005: Progression with oxaliplatin in the treatment of colorectal neoplasms].
Longo F; Mansueto G
Tumori; 2005; 91(3):suppl 1-12. PubMed ID: 16206661
[No Abstract] [Full Text] [Related]
40. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy.
Durand JP; Alexandre J; Guillevin L; Goldwasser F
Anticancer Drugs; 2005 Jun; 16(5):587-91. PubMed ID: 15846125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
